GenDx

16/04/2026

Eurobio Scientific Group signs definitive agreement to acquire CareDx’s transplant lab product division.

Through the acquisition of CareDx’s Lab Products division, the transaction brings together two highly complementary portfolios in human leukocyte antigen (“HLA”) typing and transplantation diagnostics.

“This acquisition marks a significant milestone in our mission to advance precision medicine in transplantation,” said Denis Fortier, CEO of Eurobio Scientific Group. “By combining our technological leadership with CareDx’s strong Lab Products portfolio, we are uniquely positioned to deliver comprehensive solutions to transplant laboratories worldwide.”

Read the full press release 👇https://www.gendx.com/2026/04/eurobio-scientific-signs-definitive-agreement-to-acquire-caredxs-transplant-lab-product-division/

10/04/2026

At GenDx, innovation in molecular diagnostics starts with collaboration.

In this video, we follow Eline ter Steege and Mattijs Punt, Project Managers in the R&D Reagents team, as they share what their role really looks like — beyond timelines and reporting.

From connecting multidisciplinary teams to translating research into real-world products, discover how project management helps drive innovation forward.

👉 Link to the full video in bio

10/04/2026

Three new additions to our NGSgo-AmpX v3 product line are now available.

HLA-DRB1 Whole Gene, HLA-DQB1 Whole Gene, and HLA-DPB1 Whole Gene One, expanding our high-resolution HLA typing portfolio to cover the full genomic picture.

Read more on our website 👇



https://www.gendx.com/2026/04/new-ngsgo-ampx-v3-whole-gene-for-hla-drb1-dqb1-and-dpb1/

02/04/2026

What solutions do we offer?

Navigating the full spectrum of transplant diagnostics just got easier.
We created a visual guide giving you a clear, at-a-glance overview of our pre- and post-transplant solutions.

👉 Explore the full overview in the carousel below and find the solution that fits your workflow.

📩 Ready to order or want to learn more?
Reach out to our team: sales@gendx.com

01/04/2026

NGSgo-ProntoFLX is now available as RUO. Built for single-locus HLA typing on ONT, it gives labs more flexibility.

With a ready-to-use amplification mix, labs can keep workflows simple while processing up to 96 samples in one run.
Available for HLA-A, HLA-B, HLA-DQA1, and HLA-DQB1.

Interested? Contact our team at sales@gendx.com

1 minute per sample, per locus. That’s not a typo. NGSgo-ProntoFLX is now available as RUO. Built for single-locus HLA typing on ONT, it gives labs more flex...

01/04/2026

At GenDx, innovation in molecular diagnostics starts with collaboration.

In this video, we follow Eline ter Steege and Mattijs Punt, Project Managers in the R&D Reagents team, as they share what their role really looks like — beyond timelines and reporting.

From connecting multidisciplinary teams to translating research into real-world products, discover how project management helps drive innovation forward.

👉Curious about working at GenDx?
Explore our open roles: https://www.gendx.com/careers

https://www.youtube.com/watch?v=JYy0sR0OlTI

At GenDx, innovation in molecular diagnostics starts with collaboration.In this video, we follow Eline ter Steege and Mattijs Punt, Project Managers in the R...

26/03/2026

Check out our latest blog post exploring the pivotal role of HLA in immunotherapy development👇

🔗 https://www.gendx.com/2026/03/the-role-of-hla-in-immunotherapy-development/

20/03/2026

𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗳𝗼𝗿 𝗼𝘂𝗿 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝗶𝗻 𝗔𝗽𝗿𝗶𝗹!

During this webinar, Kirsten Van Garsse (QbD Group) and Jules Petit will discuss key elements of our joint panel discussion at the 𝟭𝟲𝘁𝗵 𝗪𝗼𝗿𝗹𝗱 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗕𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝘀 & 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗼𝗻 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗦𝘂𝗺𝗺𝗶𝘁 𝗘𝘂𝗿𝗼𝗽𝗲 and dive deeper into the regulatory impact of current developments and trends in the Companion Diagnostics space.

📅 April 8
🕛 12:00 CET︱17:00 CET
📍 Online

To the registration page👇
🔗 https://www.gendx.com/2026/03/navigating-grey-zones-growing-pains-developments-in-the-regulatory-cdx-space/

Explore the principles of solid organ transplantation and the impact of HLA matching on graft survival and immune response.

19/03/2026

Let's meet at EFI/BSHI 2026!

https://www.gendx.com/2026/03/meet-gendx-at-efi-2026/

17/03/2026

More information on our website👇
https://www.gendx.com/2026/03/gendx-and-treos-bio-announce-partnership-to-develop-hla-based-companion-diagnostic-for-polypepi1018-cancer-immunotherapy/

10/03/2026

𝗝𝗼𝗶𝗻 𝗼𝘂𝗿 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝗼𝗻 𝗛𝗟𝗔 𝗶𝗻 𝗣𝗿𝗲𝗴𝗻𝗮𝗻𝗰𝘆 🤰

Michael Eikmans, PhD, assistant professor at the Department of Immunology, Leiden University Medical Center, will discuss the unique features of HLA expression at the maternal–fetal interface and the relationship of maternal-fetal HLA incompatibility to outcomes. Insight into how variations in these features may contribute to pregnancy complications will also be reviewed.

📍 Online
📅 March 17, 2026
🕛 12:00 CET │ 19:00 CET
🔗Register: https://gendx.webinargeek.com/hla-in-pregnancy

𝗔𝗯𝗼𝘂𝘁 𝘄𝗲𝗯𝗶𝗻𝗮𝗿
A successful pregnancy poses an intriguing immunological paradox: although the fetus contains genetic material from both the mother and the father, the mother’s immune system normally accepts it rather than attacking it. This tolerance is achieved through carefully balanced immune processes that support a healthy pregnancy.

Human leukocyte antigens play a pivotal role in shaping immune tolerance, fetal development, and pregnancy outcomes. There is a fascinating immunological dialogue between mother and fetus. In pregnancy, semi-allogeneic fetal trophoblasts express a specific HLA profile mediating maternal leukocyte contact, crucial for placentation. Paradoxically, maternal immunomodulation requires fetal antigen recognition, involving certain HLA molecules.

10/03/2026

Since the early days of solid organ transplantation, closer HLA matching between donor and recipient has been linked to better graft survival, and this remains true even with the presence of efficient immunosuppression. Unfortunately, due to the high polymorphism of HLA and the scarcity of donors, most organ transplants are performed with at least one or more HLA mismatches. These mismatches can trigger the recipient’s immune system to form donor-specific antibodies (DSA), which damage the graft and may lead to rejection.

Considering that not every HLA mismatch will lead to DSA formation, and that antibodies are not formed against the whole HLA molecule but rather specific areas of the HLA molecule, it is relevant to look beyond the traditional HLA matching rules.

👉 Read the full blog post written by Cynthia Kramer, PhD, Scientist at GenDx: https://www.gendx.com/2026/02/not-all-hla-are-equal-is-hla-molecular-matching-the-future-of-solid-organ-transplantation-2/